



Adalimumab Timeline



VENABLE LLP


Adalimumab Challenged Claim Types in IPR and Litigation*



*In litigations, it has been alleged that at least these claims will be infringed.


VENABLE LLP

Adalimumab IPR Status




VENABLE LLP

Adalimumab Method of Treatment Claim IPR Status



VENABLE LLP

Adalimumab Formulation Claim IPR Status



*Considering IPR2017-00826 and IPR2017-01008 as one IPR, and IPR2017-00827 and IPR2017-01009 as one IPR.

VENABLE LLP

FWD = Final Written Decision

Spotlight On: Adalimumab

July 31, 2024

Technology: Adalimumab is a human monoclonal antibody that inhibits tumor necrosis factor alpha (TNF α). TNF α is a cytokine cell signaling protein that is involved in the inflammatory response that occurs in autoimmune diseases.

| | <i>AbbVie v. Alvotech</i> 1:21-cv-02899 (N.D. Ill.) Settled (cont'd below) | <i>AbbVie v. Amgen</i> 1:16-cv-00666 (D. Del.) Settled | <i>AbbVie v. Boehringer Ingelheim</i> 1:17-cv-01065 (D. Del.) Settled | <i>AbbVie v. Alvotech</i> 1:21-cv-02258 (N.D. Ill.) Settled <i>Alvotech v. AbbVie</i> 1:21-cv-05645 (N.D. Ill.) Dismissed | <i>Amgen v. AbbVie</i> IPR2015-01514 Institution denied | <i>Amgen v. AbbVie</i> IPR2015-01517 Institution denied | <i>Coherus v. AbbVie</i> IPR2017-00822, IPR2017-00823 Institution denied | <i>Coherus v. AbbVie</i> IPR2017-00826 / IPR2017-01008 Institution denied | <i>Coherus v. AbbVie</i> IPR2017-00827 / IPR2017-01009 Institution denied |
|-----------|--|---|--|--|---|---|---|--|--|
| 8,420,081 | | | | x | | | | | |
| 8,663,945 | x | x | | | | | | | |
| 8,911,964 | x | x | | | | | | | |
| 8,916,157 | | x | | | x | | | | |
| 8,916,158 | | | | | x | x | | | |
| 8,926,975 | | | x | x | | | | | |
| 8,961,973 | | x | | x | | | | | |
| 8,986,693 | x | x | | | | | | | |
| 9,018,361 | | | x | | | | | | |
| 9,090,867 | x | | x | | | | | | |
| 9,085,619 | | | | x | | | x | x | x |
| 9,096,666 | x | x | x | | | | | | |
| 9,220,781 | | x | | | | | | | |
| 9,255,143 | | | x | | | | | | |
| 9,266,949 | x | | x | | | | | | |
| 9,272,041 | | x | x | | | | | | |
| 9,359,434 | x | x | | | | | | | |
| 9,365,645 | | x | | | | | | | |
| 9,546,212 | x | | x | | | | | | |

FWD = Final Written Decision

Spotlight On:
Adalimumab

July 31, 2024

| | <i>AbbVie v. Alvotech</i> 1:21-cv-02899 (N.D. Ill.) Settled (cont'd) | <i>Coherus v. AbbVie</i> IPR2016-00172 FWD: All claims unpatentable; Appeal No. 17-2304 Affirmed (U.S. as Intervenor, Coherus settled) | <i>Boehringer Ingelheim v. AbbVie</i> IPR2016-00408, IPR2016-00409 FWD: All claims unpatentable; Appeal Nos. 17-2362 and 17-2363 Affirmed (U.S. as Intervenor, Boehringer Ingelheim settled) | <i>Coherus v. AbbVie</i> IPR2016-00188 FWD: All claims unpatentable; Appeal No. 17-2305 Affirmed (U.S. as Intervenor, Coherus settled) | <i>Coherus v. AbbVie</i> IPR2016-00189 FWD: All claims unpatentable; Appeal No. 17-2306 Affirmed (U.S. as Intervenor, Coherus settled) | <i>Sandoz v. AbbVie</i> IPR2017-01824 Institution denied; Request for rehearing denied; Appeal No. 18-2142 settled | <i>Sandoz v. AbbVie</i> IPR2018-00002 Institution denied; Appeal No. 18-2143 settled |
|------------|--|---|--|---|--|--|--|
| 8,889,135 | | x | x | | | | |
| 9,017,680 | | | | x | | | |
| 9,073,987 | | | | | x | | |
| 9,512,216 | x | | | | | x | x |
| | | <i>Sandoz v. AbbVie</i> IPR2017-01823 Institution denied | <i>Sandoz v. AbbVie</i> IPR2017-01987 Institution denied; Settled during request for rehearing | <i>Sandoz v. AbbVie</i> IPR2017-01988 Institution denied; Settled during request for rehearing | <i>Sandoz v. AbbVie</i> IPR2017-02106 Settled after institution Coherus settled) | <i>Sandoz v. AbbVie</i> IPR2017-02105 Settled after institution | <i>Coherus v. AbbVie</i> IPR2016-01018 Institution denied |
| 8,802,100 | | x | | | | | |
| 8,911,737 | x | | x | | | | |
| 8,974,790 | x | | | x | | | |
| 9,067,992 | x | | | | x | | |
| 9,090,689 | x | | | | | x | |
| 9,114,166 | | | | | | | x |
| | | <i>Sandoz v. AbbVie</i> IPR2018-00156 Institution denied | | <i>AbbVie v. Sandoz</i> 3:18-cv-12668 (D.N.J.) Settled | | <i>Coherus v. Amgen</i> [Related to Amjevita™] 1:19-cv-00139 (D. Del.) Settled | |
| 9,187,559 | x | x | | x | | | |
| 9,750,808 | | | | x | | | |
| 10,155,039 | | | | | | | x |
| 10,159,732 | | | | | | | x |
| 10,159,733 | | | | | | | x |
| 10,207,000 | | | | | | | x |

FWD = Final Written Decision

Spotlight On:
Adalimumab

July 31, 2024

| <i>AbbVie v. Alvotech</i> 1:21-cv-02899 (N.D. Ill.) Settled (cont'd) | | | | | |
|--|---|-----------|---|-----------|---|
| 6,805,686 | x | 9,090,688 | x | 9,550,826 | x |
| 8,231,876 | x | 9,102,723 | x | 9,624,295 | x |
| 8,708,968 | x | 9,150,645 | x | 9,669,093 | x |
| 8,715,664 | x | 9,181,337 | x | 9,683,033 | x |
| 8,808,700 | x | 9,181,572 | x | 9,708,400 | x |
| 8,883,156 | x | 9,234,032 | x | 9,957,318 | x |
| 8,889,136 | x | 9,273,132 | x | | |
| 8,895,009 | x | 9,284,370 | x | | |
| 8,906,372 | x | 9,284,371 | x | | |
| 8,906,373 | x | 9,290,568 | x | | |
| 8,906,646 | x | 9,315,574 | x | | |
| 8,916,153 | x | 9,328,165 | x | | |
| 8,961,974 | x | 9,334,319 | x | | |
| 8,992,926 | x | 9,339,610 | x | | |
| 8,999,337 | x | 9,346,879 | x | | |
| 9,061,005 | x | 9,499,614 | x | | |
| 9,062,106 | x | 9,499,616 | x | | |
| 9,085,618 | x | 9,505,834 | x | | |
| 9,085,620 | x | 9,522,953 | x | | |

FWD = Final Written Decision